ストックスクリーナーアプリを入手
6.10
0.07%
0.05
前日終値:
$6.05
開ける：
$5.865
24時間の取引高:
5,969
Relative Volume:
0.02
時価総額：
$33.24M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+9.68%
1か月 パフォーマンス:
+9.88%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.865
$6.09
1週間の範囲:
$5.30
$6.10
52週間の値動き範囲:
$4.71
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
HIND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
6.09 | 33.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.74 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
640.57 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.54 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.40 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.00 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vyome Holdings Inc (HIND) 最新ニュース
Comparing Anzu Special Acquisition Corp I (NASDAQ:ANZUW) & Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings, Inc.Common Stock (Nasdaq:HIND) Stock Quote - FinancialContent
Vyome Holdings Elects Directors at Annual Meeting - TipRanks
Head-To-Head Contrast: Vyome (NASDAQ:HIND) & TranS1 (OTCMKTS:BAXSQ) - Defense World
ReShape Lifesciences : trade; to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate UpdateForm 8-K/A - MarketScreener
Tincoff John M. Iii Net Worth (2025) - GuruFocus
ReShape Lifesciences (OTCMKTS:RSLSD) versus Vyome (NASDAQ:HIND) Financial Survey - Defense World
Will Vyome's Topical Gel Be The First FDA-Approved Treatment For Cancer Wounds? - RTTNews
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Maxim Group Reaffirms “Buy” Rating for Vyome (NASDAQ:HIND) - Defense World
Vyome Holdings Acquires AI Startup Oculo, Inc. - TipRanks
HIND Analyst Forecasts - Quiver Quantitative
Vyome Holdings acquires Oculo Health - Medical Buyer
Vyome Holdings Acquires MIT Spinout Oculo Health, Launches AI Psychiatrist Business Unit - Sahyadri Startups
Vyome Holdings Acquires MIT AI Spinout Oculo Health - citybiz
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics By Investing.com - Investing.com South Africa
Vyome acquires AI startup Oculo to develop inflammation-focused digital therapeutics - Investing.com Nigeria
Vyome Holdings acquires MIT AI spinout Oculo Health - MarketScreener
Vyome shares surge after encouraging preclinical data for eye treatment - MSN
BC-Most Active Stocks - upstatetoday.com
Why Is BBAI Stock Falling Today? - Stocktwits
HIND Stock Rallies 70% Pre-Market Today Find Out Why - Menafn
HIND Stock: Growth or Bubble? - StocksToTrade
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Asianet Newsable
Vyome Holdings (HIND) Skyrockets Over 50% on Breakthrough Uveitis Treatment News - RagingBull
Vyome stock soars after positive preclinical results for eye drug - Investing.com India
Vyome stock soars after positive preclinical results for eye drug By Investing.com - Investing.com Nigeria
Morning Market Movers: SPRC, HIND, SQFT, FGNX See Big Swings - RTTNews
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity - Business Wire
Vertiv’s Stock Surge: Will it Last? - StocksToTrade
Vyome Holdings Appoints Dr. Richard Fahrner as CTO and Dr. Tamara Agajanov, MD, as SVP – Clinical Development - citybiz
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Nigeria
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Therapeutics2025 Latest Shareholding - Tracxn
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com India
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com Canada
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome Holdings, Inc. (HIND) Company Profile & Facts - Yahoo
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
Vyome Holdings Inc (HIND) 財務データ
Vyome Holdings Inc (HIND) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.03%
0.32%
大文字化:
|
ボリューム (24 時間):